Parapneumonic effusions related to *Streptococcus pneumoniae*: serotype and disease

2 severity trends from 2006 to 2018 in Bristol, UK

- 3 Catherine Hyams MB PhD, Academic Respiratory Unit and Bristol Vaccine Centre,
- 4 University of Bristol, Bristol, UK. ORCID: 0000-0003-3923-1773
- 5 David T Arnold PhD, Academic Respiratory Unit, University of Bristol, Bristol, UK. ORCID
- 6 0000-0003-3158-7740
- 7 Robyn Heath, MA. Vaccine and Testing Research Team, Clinical Research Facility, St
- 8 Michael's Hill, Bristol Royal Infirmary, Bristol, United Kingdom
- 9 Zahin Amin-Chowdhury MSc. National Infection Service, UKHSA, London, United
- 10 Kingdom

- 11 David Hettle MBChB. Microbiology Services Bristol, Bristol Royal Infirmary and North
- 12 Bristol NHS Trust, Bristol, United Kingdom. ORCID: 0000-0002-7606-986X
- 13 Gabriella Ruffino MBChB, Academic Respiratory Unit and Bristol Vaccine Centre,
- 14 University of Bristol, Bristol, UK. ORCID: 0000-0002-1549-9364
- 15 Paul North BSc, Microbiology Services Bristol, Bristol Royal Infirmary and North Bristol
- 16 NHS Trust, Bristol, United Kingdom.
- 17 Charli Grimes BSc, Academic Respiratory Unit and Bristol Vaccine Centre, University of
- 18 Bristol, Bristol, UK. ORCID: 0000-0002-0171-0704
- 19 Norman K Fry PhD, National Infection Service, UKHSA, London, United Kingdom.
- 20 ORCID: 0000-0003-4862-6507
- 21 Philip Williams PhD, Microbiology Services Bristol, Bristol Royal Infirmary and North
- 22 Bristol NHS Trust, Bristol, United Kingdom.
- 23 Robert Challen PhD, Engineering Mathematics, University of Bristol, Bristol, United
- 24 Kingdom
- 25 Leon Danon PhD, Engineering Mathematics, University of Bristol, Bristol, United Kingdom
- 26 O Martin Williams PhD, Microbiology Services Bristol, Bristol Royal Infirmary and North
- 27 Bristol NHS Trust, Bristol, United Kingdom.
- 28 Shamez Ladhani PhD, National Infection Service, UKHSA, London, United Kingdom.
- 29 ORCID: 0000-0002-0856-2476
- 30 Adam Finn PhD, Bristol Vaccine Centre, University of Bristol, Bristol, UK. ORCID: 0000-
- 31 0003-1756-5668

33

343536

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

5253

54

55

56

57

58 59

60

61

62

63

64

65

Nick A Maskell MD, Academic Respiratory Unit, University of Bristol, Bristol, UK. ORCID: 0000-0002-1276-6500 **Corresponding address:** Dr Catherine Hyams, MBBS BSc(Hons) PhD MRCP Academic Respiratory Unit, Learning & Research Building, Southmead Hospital, Bristol, BS10 5NB catherine.hyams@bristol.ac.uk **Descriptor:** 9.31 Pleural Diseases/Mesothelioma Running head: Pneumococcal related parapneumonic effusions **Keywords:** Streptococcus pneumoniae; Empyema; Pleural disease; bacterial infection; respiratory infection. **Author Contributions:** CH, DA, AF, OMW and NM generated the research questions and analysis plan. CH, RH, DH, GF, DA, PN, PW, ZAC collected data. CH and DH verified the data. CH, RC, DA, RH, AF and NM undertook the data analysis. AF, OMW and NM provided oversight of the research. AF and CH verified the data. All authors contributed to the preparation of the manuscript and its revision for publication and had responsibility for the decision to publish. **Funding:** CH was funded by the National Institute for Health Research [NIHR Academic Clinical Fellowship (ACF-2015-25-002). DTA was funded by an NIHR Doctoral Research Fellowship (DRF-2018-11-ST2-065). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. **Declarations:** CH is Principal Investigator of the AvonCAP study which is an investigatorled University of Bristol study funded by Pfizer. AF is a member of the Joint Committee on Vaccination and Immunization (JCVI) and chair of the World Health Organization European Technical Advisory Group of Experts on Immunization (ETAGE) committee. In addition to receiving funding from Pfizer as Chief Investigator of this study, he leads another project investigating transmission of respiratory bacteria in families jointly funded by Pfizer and the

Gates Foundation. The other authors have no relevant conflicts of interest to

declare.

68 **Word Count:** 3,331

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

ABSTRACT Rationale Streptococcus pneumoniae epidemiology is changing in response to vaccination and some data suggest empyema incidence is increasing. However, differences exist between UK and USA studies. We describe trends in the clinical phenotype of adult pneumococcal pleural infection, including simple parapneumonic effusions (SPE) in the pneumococcal conjugate vaccination (PCV) era. **Objectives:** To determine whether there were differences in pneumococcal disease presentation and severity associated with pleural infection. Methods A retrospective cohort study, all adults ≥16 years admitted to three large UK hospitals, 2006-2018 with pneumococcal disease. 2477 invasive pneumococcal cases were identified: 459 SPE and 100 pleural infection cases. Medical records were reviewed for each clinical episode. Serotype data were obtained from the UK Health Security Agency national reference laboratory. Results Incidence increased over time, including non-PCV-serotype disease. PCV7-serotype disease declined following paediatric PCV7 introduction, but the effect of PCV13 was less apparent as disease caused by the additional six serotypes plateaued with serotypes 1 and 3 causing such parapneumonic effusions from 2011 onwards. Patients with pleural infection had a median survival 468 days (95% CI 340-590), versus 286 days (95% CI 274-335) in those with SPE. Pleural infection associated with frank pus had

92 lower 90-day mortality than pleural infection without pus (0% versus 29%, P<0.0001). 90-93 day mortality could be predicted by baseline increased RAPID (Renal, Age, Purulence, 94 Infection source, and Dietary factors) score (HR15.01, 95% CI 1.24-40.06, *P*=0.049). 95 **Conclusions** 96 Pneumococcal infection continues to cause severe disease despite the introduction of PCVs. 97 The predominance of serotype 1 and 3 in this adult UK cohort is in keeping with previous 98 studies in paediatric and non-UK studies. Rising non-PCV serotype disease and limited 99 impact of PCV13 on cases caused by serotypes 1 and 3 offset the reductions in adult 100 pneumococcal parapneumonic effusion disease burden observed following introduction of the 101 childhood PCV7 programme.

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

KEY MESSAGES What is already known on this topic The epidemiology of pneumococcal infection is changing in both adults and children following pneumococcal conjugate vaccine (PCV) introduction, as a result of direct and indirect vaccine effects. Other studies have reported that serotypes 1 and 3 disproportionately cause pneumococcal pleural disease; however, the clinical phenotype of parapneumonic effusions associated with pneumococcal infection in adults following PCV introduction is not well described. What this study adds In this study which presents the largest cohort of patients with a single-organism pleural infection, we demonstrate an increasing incidence of parapneumonic effusions related to Streptococcus pneumoniae in adults, attributable to serotype 1 and 3 disease, despite the introduction of PCV13 in the UK childhood vaccination programme. Interestingly, our data suggest that pneumococcal pleural infection is associated with improved survival up to oneyear compared to patients with pneumococcal simple parapneumonic effusions. How this study might affect research, practice or policy Careful assessment of the need for specialist respiratory and thoracic surgical intervention in the context of increasing incidence of adult parapneumonic effusions related to *Streptococcus* pneumoniae will be required, in addition to ongoing monitoring of the effect on serotype distribution and clinical phenotype of current and future vaccines against pneumococcus.

INTRODUCTION

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

Streptococcus pneumoniae remains the leading bacterial cause of community-acquired pneumonia (CAP), despite vaccine deployment. Approximately 15-20% hospitalised pneumococcal CAP cases are associated with a pleural effusion ¹² and 6% with empyema ¹³. The morbidity and mortality associated with simple parapneumonic effusion (SPE) are higher than with uncomplicated pneumonia⁴. Several USA studies have shown that pneumococcal conjugate vaccine (PCV, a vaccine comprised of pneumococcal polysaccharides conjugated to a non-toxic diphtheria protein) introduction resulted in a significant reduction in both carriage and invasive pneumococcal disease (IPD) due to vaccine serotypes, especially in children⁵⁶. Increasing pneumococcal empyema rates in children have been reported⁷ although the effect of paediatric PCV deployment on adult disease phenotype is debated⁸. Recent evidence suggests that incidence of pneumococcal empyema, especially in adults aged >65 years, has increased following paediatric PCV deployment, possibly due to serotype 1 or 3 emergence⁹. Thus, vaccine-driven serotype replacement may be leading to changes in pneumococcal disease phenotype and severity. A dose of PPV-23 (unconjugated 23-valent polysaccharide vaccine) is offered to all adults ≥65 years in the UK, and ≥2-year-olds with at least one clinical risk factor for pneumococcal disease also receive this vaccine¹⁰. A 7-valent PCV was introduced into the UK childhood vaccination programme in 2006, subsequently replaced in April 2010 with a 13-valent PCV (PCV13) and the schedule was modified in 2020 so that only two vaccine doses are now given (one at 12 weeks of age, followed by a booster at 12-13 months of age). By 2016/17 in the UK, PCV7 serotype pneumococcal disease in children had virtually disappeared and PCV7 disease significantly reduced in adults. In contrast, PCV13 serotype disease has not

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

disappeared, but plateaued, with a remaining residual incidence of 7.97 per 100,000 across all age groups and disease attributable to non-PCV13 serotypes has increased, especially in the elderly¹¹⁻¹³. Evidence from a large pneumococcal pneumonia patient cohort in Nottingham, UK suggests that, aside from age, residential care status and some comorbidities, there are relatively few differences between patients with respiratory infection caused by PCV13 and those with non-PCV13 serotype infections¹⁴. Here we present the largest cohort of patients with a single-organism pleural infection, encompassing simple parapneumonic effusion (SPE)¹⁵ and pleural infection (complex parapneumonic effusion (CPE) or empyema)^{3 15} attributable to pneumococcus, in this singlecentre observational study covering thirteen years during which PCVs were introduced into the UK paediatric vaccination programme. We sought to determine the incidence of parapneumonic effusions in adults, overall and by vaccine-serotype group. Additionally, we aimed to describe differences in pneumococcal disease presentation and severity associated with pleural infection, given concerns surrounding changing pneumococcal serotype distribution and serotype 1 and 3 pleural infection.

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

MATERIALS AND METHODS **Study Subjects** Patients aged ≥16 years admitted to all three hospitals providing emergency care in Bristol and Bath (University Hospitals Bristol and Weston, North Bristol and The Royal United Hospital NHS Trusts) between January 2006 and December 2018, with a confirmed microbiological diagnosis of pneumococcal infection were eligible for this study. This study was approved by the Health Research Authority, UK (IRAS 265437). **Study Design** A retrospective cohort study at three large NHS hospitals in the UK. Patient and public involvement There was no patient or public involvement in the undertaking of this study. Methods Study-eligible cases were identified retrospectively by searching the Laboratory Information Management System (LIMS) database (Clinisys WinPath Enterprise). S. pneumoniae was confirmed on culture from sterile-site sampling at a central laboratory using standard microbiological techniques combined with API®-20 Strep (BioMérieux, UK) or MALDI-TOF (matrix-assisted laser desorption/ionisation/time of flight) mass spectrometry (Bruker, UK) ¹⁶. A positive pneumococcal urinary-antigen test (BinaxNOW®, Alere, UK) was also considered confirmative of pneumococcal infection. Patients were included if they tested

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

positive on either or both tests. Any patient with pleural fluid which cultured a singleorganism which was not pneumococcus was excluded from this cohort; although, multiorganism pleural infection including pneumococcus was included. Confirmed cases were linked with the UK Health Security Agency (UKHSA) national reference laboratory to obtain serotype data ¹⁷ which were collected separately from clinical data to avoid any risk of bias in data collection. Pneumococcal serotypes were grouped by PCV (PCV7; PCV13-7 representing the additional 6 serotypes in PCV13; and PCV13) or as non-PCV (Supplementary Data 1). Patients with pneumococcal infection and a pleural effusion on radiology were either classified as: (1) pleural infection: if pleural fluid was pus or bacterial culture positive (i.e. an empyema)³; an effusion relating to a current pneumonia episode which necessitated definitive drainage (e.g. thoracic surgery); or, there was an exudative effusion 18 with pH $\leq 7.2^3$; or, (2) SPE: an exudative effusion not classified as pleural infection in a patient with a clinical and/or radiological diagnosis of pneumonia¹⁵. Patients' clinical records were reviewed at each hospital and data, including clinical outcomes, recorded. The vaccination status of each patient was established from electronically linked GP records¹⁶. The CURB65 severity score on admission was calculated for each clinical episode¹⁹. Patients with pleural infection had a RAPID (Renal, Age,

Purulence, Infection source, and Dietary factors) score calculated²⁰, which has been validated to stratify adults with pleural infection according to increasing risk of mortality²¹.

Study objectives

The primary objective was to determine trends in pneumococcal pleural disease incidence between 2006 and 2020, both overall and by vaccine-serotype groups, in the context of the UK vaccination programme. Secondary objectives included determining if any changes in disease incidence were attributable to emergence of either vaccine-serotype groups or specific serotypes, as well as describing differences in pneumococcal disease presentation and disease severity associated with pleural infection.

Analysis

Patient data are reported as medians and interquartile ranges (IQR) for continuous variables, or means and standard deviations where their distribution was confirmed to be normal using the Anderson Darling normality test. Categorical variables are presented as counts and percentages. Baseline characteristics and comorbid risk factors for SPE and pleural infection were compared using Fisher's exact tests for categorical variables, and the two-sample Wilcoxon Rank Sum test for non-parametric continuous variables, or 2 sided student's t-test for parametric continuous variables. Comparisons were not performed where missing data was present. *P*-values are presented unadjusted but the level at which a result was considered significant was reduced in recognition of the fact multiple comparisons were made. Patient survival was assessed at two years (730 days) following hospital admission, with this being the time of right censoring, and a median survival calculated. Time series trends for serotype proportions were estimated using a 5-knot natural spline, fitted to a quasi-binomial model,

using a logistic link function in a maximum likelihood estimation framework, The Kaplan–Meier (KM) method and Cox proportional hazard regression model were used for calculation of survival at 30-, 90- and 365-days following first positive pneumococcal microbiological test. Proportional hazard assumptions were tested by visual assessment of the KM survival curve, log(-log) plots and Schoenfeld residuals. Survival differences were analyzed using the log-rank test. Statistical analysis was performed using SPSS, version 28.0 (New York, IBM) or with R v4.0.2. Graphs were generated in GraphPad PRISM, version 9.0.

RESULTS

2657 episodes of pneumococcal infection were identified, of which 2447 were respiratory infections: 1888 pneumonia-only cases, 459 with SPE and 100 cases including pleural infection (Supplementary Data 2). In total, 282/559 (50%) were male with a median age of 68y (IQR 50-78) (Table 1). Patients with pleural infection were younger than those with SPE (median ages 55 vs 71y respectively, P<0.001), were more likely to have history of cardiac disease (P<0.015) and less likely to develop bilateral effusions (P<0.001). On presentation to hospital, neither clinical observations nor CURB65 score differed significantly between patients with SPE and pleural infection (P=0.024); in contrast, patients with pleural infection had significantly greater C-reactive protein levels, and other inflammatory markers including white cell count and neutrophil count were tending towards elevation (Table 1).

Table 1: Clinical features of patients with pneumococcal parapneumonic effusions

251

Variable	Characteristic	All parapneumonic	SPE	Pleural	P value *	
		effusions	V-1 (N. 450)	infection		
Cturante a a a a a a a a a a a a a a a a a a a	u audu a dia amasia	Value (N=559)	Value (N=459)	Value (N=100)		
Streptococcus pneum Micro	Blood culture %	50.60/ (202)	52.10/ (220)	44.00/ (44)	0.15	
confirmation**	(N)	50.6% (283)	52.1% (239)	44.0% (44)	0.15	
	Urine antigen test % (N)	49.4% (276)	47.9% (220)	56.0% (56)		
Pleural culture	Negative % (N)	92.5% (517)	100.0% (459)	58.0% (58)	< 0.001	
	S. pneumoniae % (N)	4.8% (27)	0.0% (0)	27.0% (27)		
	Multi-organism % (N)	2.7% (15)	0.0% (0)	15.0% (15)		
Demographics and ((I	
Gender	Male % (N)	50.4% (282)	50.1% (230)	52.0% (52)	0.74	
	Female % (N)	49.6% (277)	49.9% (229)	48.0% (48)	1	
Age (years)	Median [IQR]	68 [50—80.5]	71 [54—82]	55 [45—73.2]	< 0.001	
Smoking status	Non-smoker % (N)	22.9% (128)	23.1% (106)	22.0% (22)	0.0068	
	Current smoker % (N)	35.1% (196)	32.2% (148)	48.0% (48)		
	Ex-smoker % (N)	42.0% (235)	44.7% (205)	30.0% (30)	-	
Chronic lung disease	` '	43.8% (245)	44.2% (203)	42.0% (42)	0.74	
Cardiac disease	Rate % (N)	53.3% (298)	55.8% (256)	42.0% (42)	0.015	
Upper GI	Rate % (N)	38.3% (214)	39.2% (180)	34.0% (34)	0.36	
Cerebrovascular disease	Rate % (N)	7.0% (39)	7.4% (34)	5.0% (5)	0.52	
Type 2 Diabetes	Rate % (N)	17.0% (95)	17.4% (80)	15.0% (15)	0.66	
Chronic Liver Failure	Rate % (N)	4.5% (25)	4.6% (21)	4.0% (4)	1	
Intravenous Drug Usage	Rate % (N)	4.3% (24)	3.7% (17)	7.0% (7)	0.17	
Alcohol excess	Rate % (N)	9.5% (53)	8.3% (38)	15.0% (15)	0.057	
BMI ≤17 or ≥35	Rate % (N)	4.1% (23)	3.3% (15)	8.0% (8)	0.047	
CURB-65 Score					1	
CURB-65 on	0 % (N)	24.5% (137)	22.4% (103)	34.0% (34)	0.024	
admission	1 % (N)	24.5% (137)	24.4% (112)	25.0% (25)		
	2 % (N)	26.1% (146)	28.3% (130)	16.0% (16)		
	3 □ 5 % (N)	24.9% (139)	24.8% (114)	25.0% (25)	-	
Laboratory Tests an		` '	(/			
White cell count,	Mean ± SD	17.9 ± 8.19	17.5 ± 8.02	19.9 ± 8.71	0.011	
×10 □/L						
Neutrophil count, ×10□/L	Median [IQR]	14.9 [10—20.2]	14.2 [9.9—20.1]	23.9]	0.0028	
C-reactive protein, mg/dL	Median [IQR]	215 [132—341]	200 [129—312]	338 [204—412]	_	
Albumin, g/dL	Median [IQR]	30 [26—36]	31 [27—36]	28 [23—34]	< 0.001	
Urea, mmol/L	Median [IQR]	9.3 [6.4—13.2]	9.2 [6.5—13.3]	9.8 [5.97—12.8]	0.67	
Bilateral effusion Outcomes	Rate % (N)	24.9% (139)	28.1% (129)	10.0% (10)	<0.001	

Acute Renal	Rate % (N)	35.4% (198)	37.3% (171)	27.0% (27)	0.064
Failure†					
Liver dysfunction#	Rate % (N)	10.7% (60)	12.0% (55)	5.0% (5)	0.048
ITU admission	Rate % (N)	20.2% (113)	20.3% (93)	20.0% (20)	1
Increased care	Rate % (N)	35.4% (198)	38.3% (176)	22.0% (22)	0.0018
needed					
Admission days	Median [IQR]	11 [6—20]	10 [5—19.5]	15 [10—21]	< 0.001
Mortality					
Inpatient mortality	Rate % (N)	12.7% (71)	13.1% (60)	11.0% (11)	0.74
30-day mortality	Rate % (N)	13.2% (74)	14.2% (65)	9.0% (9)	0.19
90-day mortality	Rate % (N)	19.0% (106)	20.5% (94)	12.0% (12)	0.05
1-year mortality	Rate % (N)	27.0% (151)	29.2% (134)	17.0% (17)	0.013

* Significance determined using Fisher's exact test (categorical variables) or 2 sample Wilcoxon Rank Sum test (continuous variables). Normality of distributions determined using Anderson-Darling normality test. Due to the fact multiple comparisons are made we consider the level of significance required to exclude the null hypothesis to be 0.0017 (0.05/30).

** Patients were included if they tested positive for pneumococcus on sterile site culture and/or urinary antigen test. Therefore some patients tested positive for both tests.

† Acute renal failure was defined as a reduction in renal function (as measured by creatinine or eGFR), oliguria (<400ml urine per 24h) or clinical diagnosis of acute kidney injury # Liver dysfunction was defined as a transient disorder of hepatic function characterized by either liver enzymes, or clinical diagnosis of acute liver dysfunction. Other features of acute liver failure may or may not be present, including jaundice, vomiting, coagulopathy, hyperbilirubinemia, and increased serum lactate

Annual incidence of *S. pneumoniae* parapneumonic effusions increased throughout the study period (Figure 1A) with a 33% and 34% increase in unplanned hospital admissions and microbiological testing between 2006 and 2018 (Supplementary Data 4), indicating relative increase in hospital workload was not equivalent to the increase in disease incidence. The age of patients admitted throughout the study did not show any apparent trend (Supplementary Data 5). In 38% cases serotype was available, of which overall 52% were attributable to a PCV13 serotype while only 8% were caused by a non-vaccine serotype. There was an absolute and proportional decrease in disease caused by PCV7 serotypes (Figure 1). PCV13-7 disease showed an initial rise, followed by a fall after PCV13 introduction with a gradual rise in disease over the last 5 study years (Figure 1B). The only PCV13-7 serotypes that caused pneumococcal pleural infections after 2010 were 1 and 3: 2 (17% of serotype known disease)

and 3 (25%) pre-2010 pleural infection cases versus 9 (30%) and 7 (23%) post-2010 pleural infection cases due to serotype 1 and 3 respectively (Supplementary Data 6). Serotype 1 affected younger patients than serotype 3 but was associated with higher RAPID severity group (high RAPID severity group 36% versus 17%, *P*<0.0001) and a trend towards increased rates of renal failure (77% versus 43%, *P*=0.023) than seen in patients with serotype 3 parapneumonic effusions (Table 2). After 2011, all PCV7 disease was attributable to serotypes 14 and 19F, with all PCV7 disease being SPE and no cases of pleural infection.

Table 2: Clinical features of patients with serotype 1 and 3 pneumococcal parapneumonic effusions

Variable	Characteristic	Serotype 1	Serotype 3	P value *	
		N=22	N=30		
Demographics and Com	orbidities	'		1	
Gender	Male % (N)	59.1% (13)	53.3% (16)	0.78	
	Female % (N)	40.9% (9)	46.7% (14)		
Age (years)	Mean ± SD	53.4 ± 18.9	72.5 ± 15.9	< 0.001	
Smoking status	Non-smoker % (N)	27.3% (6)	23.3% (7)	0.45	
	Current smoker % (N)	50.0% (11)	36.7% (11)		
	Ex-smoker % (N)	22.7% (5)	40.0% (12)		
Chronic lung disease	Rate % (N)	45.5% (10)	40.0% (12)	0.78	
Cardiac disease	Rate % (N)	40.9% (9)	70.0% (21)	0.049	
Upper GI	Rate % (N)	13.6% (3)	36.7% (11)	0.11	
Cerebrovascular disease	Rate % (N)	0.0% (0)	10.0% (3)	0.25	
Type 2 Diabetes	. ,		23.3% (7)	0.74	
Chronic Liver Failure	` ` ´		6.7% (2)	0.5	
Intravenous Drug Usage	ravenous Drug Usage Rate % (N)		3.3% (1)	1	
Alcohol excess Rate % (N)		9.1% (2)	13.3% (4)	1	
Pleural Features					
Pleural infection	Rate % (N)	50.0% (11)	33.3% (10)	0.26	
Loculation	Rate % (N)	22.7% (5)	10.0% (3)	0.26	
Pus	Rate % (N)	18.2% (4)	20.0% (6)	1	
RAPID Group	Low % (N)	50.0% (11)	16.7% (5)	< 0.001	
	Medium % (N)	13.6% (3)	66.7% (20)		
	High % (N)	36.4% (8)	16.7% (5)		
Outcomes		<u>, </u>	-		
Acute Renal Failure†	Rate % (N)	77.3% (17)	43.3% (13)	0.023	
Liver dysfunction#	iver dysfunction# Rate % (N)		3.3% (1)	0.57	
TU admission Rate % (N)		18.2% (4)	20.0% (6)	1	
Increased care needed Rate % (N)		27.3% (6)	33.3% (10)	0.76	
Admission days	* * *		10 [4.25—18]	0.37	
Inpatient mortality Rate % (N)		4.5% (1)	23.3% (7)	0.12	

30-day mortality	Rate % (N)	9.1% (2)	20.0% (6)	0.44
90-day mortality	Rate % (N)	13.6% (3)	36.7% (11)	0.11
1-year mortality	Rate % (N)	18.2% (4)	46.7% (14)	0.042

* Significance determined using Fisher's exact test (categorical variables) or 2 sample Wilcoxon Rank Sum test, or student's t-tests (continuous variables). Normality of distributions determined using Anderson-Darling normality test. *P*-values were considered significant if they were under 0.002 (0,05/24).

† Acute renal failure was defined as a reduction in renal function (measured by creatinine or eGFR), oliguria (<400ml urine per 24h) or clinical diagnosis of acute kidney injury

Liver dysfunction was defined as a transient disorder of hepatic function characterized by either liver enzymes, or clinical diagnosis of acute liver dysfunction. Other features of acute liver failure may or may not be present.

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

Overall, 19% patients with pneumococcal parapneumonic effusions died within 90-days of presentation (Table 1, Supplementary Table 7). Patients with pleural infections had higher survival rates than those with SPE at 30-, 90- and 365-days (P<0.01) (Figure 2A). The mortality rate among patients with pleural infection increased alongside RAPID score severity at 30-, 90- and 365-days (Figure 2B, Table 3A), and a high RAPID score was associated with a median survival of 56 days (20-154 days, 95% CI). Proportional hazards regression analysis supported the earlier finding that more severe RAPID group was associated with increased 90-day (P=0.049, 95% CI 1.24-40.06) and 365-day mortality (*P*=0.034, 95% CI 1.09-51.2) (Table 3B). Median survival was 468 days (340-590 days, 95% CI) in patients with pleural infection, vs 286 (274-335 days, 95% CI) in those with SPE. In total, 59/100 (59%) pleural infection patients had pus and these patients had improved 30-, 90-, and 365-day mortality compared to those without pus; in contrast, loculation was associated with reduced 30-, 90- and 365-day mortality (Table 3B). Surgical management was associated with improved prognosis: no deaths occurred within 1-year of presentation compared to 24% mortality in patients with pleural infection who did not undergo surgery. Patients undergoing thoracic surgery were younger than those who did not (median age 45 years, IQR40-52 versus 66 years, IQR53-78).

Table 3: Mortality and Risk Analysis in patients with pleural infection cases (A) Mortality among 100 pneumococcal pleural infection cases with different clinical features and RAPID severity Scores

Characteristic	Pleural Infection				
	Total Patients	30 Day	90 Day	365 Day	
	(N=100)	Mortality	Mortality	Mortality	
		N (%)	N (%)	N (%)	
Disease Characteristics					
Pus	59	0 (0)	0 (0)	1 (2)	
No Pus	41	9 (22)	12 (29)	12 (29)	
Loculation Present	49	8 (16)	10 (20)	12 (25)	
No loculation Detected	51	1(2)	2 (4)	5 (10)	
Fibrinolytics used	33	4 (12)	6 (18)	11 (33)	
Surgical Management *	29	0 (0)	0 (0)	0 (0)	
- Loculation present	23	0 (0)	0 (0)	0 (0)	
- No loculation	6	0 (0)	0 (0)	0 (0)	
No Surgical Management	71	9 (13)	12 (17)	17 (24)	
RAPID Risk Group					
Low	36	1 (3)	1 (3)	3 (8)	
Medium	46	2 (4)	3 (7)	4 (9)	
High	18	6 (33)	10 (55)	13 (72)	

(B) Cox Regression Analysis for risk factors in patients with pleural infection

Analysis	Fac	ctor	Beta (β) estimate	HR	95% CI	<i>P</i> -value
30-day	RAPID Group	Low Medium High	13.52 28.51	- 12.04 19.33	- 0.23-39.87 0.55-92.33	0.674 0.638
mortality	Age Loculation		-0.002 1.705	0.998 5.502	0.96-1.05 0.99-103	0.921 0.111
90-day mortality	RAPID Group	Low Medium High	0.573 2.709	- 1.773 15.01	- 0.19-38.77 1.24-40.06	0.642 0.049
	Age Loculation		0.015 1.582	1.02 4.86	0.97-1.07 1.27-31.87	0.550 0.043
365-day mortality	RAPID Low Group Medium Age High		0.573 2.709	1.773 15.01	0.19-38.77 1.24-40.06	0.642 0.049
	Age Loculation		0.027 1.041	1.028 2.836	0.99-1.07 1.04-9.00	0.188 0.050

^{* 18} patients underwent surgery after fibrinolytic usage

326 RAPID (Renal, Age, Purulence, Infection source, and Dietary factors) Score 0-2 represents

327 low risk, 3-4 medium risk and 5-7 high risk

328 Proportional hazard assumptions were tested by visual assessment of the KM survival curve,

329 log(-log) plots and Schoenfeld Residuals (Supplementary Data 8)

DISCUSSION

319

320

321

322 323

324 325

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

This observational cohort study, with data from a 13-year period spanning PCV introduction into the UK childhood vaccination programme, presents data clearly showing increasing adult pneumococcal parapneumonic effusion disease incidence. The proportion of disease attributable to PCV7 serotypes fell after this vaccine was introduced into the UK childhood vaccination programme; however, disease attributable serotypes 1 and 3 did not show decline following PCV13 vaccine rollout. Further increase in non-vaccine serotype disease contributed to increasing disease incidence. Both overall admissions and microbiological testing at the study hospitals increased progressively during our study period, but not as much as disease incidence, suggesting these did not solely account for the increasing incidence observed. An increasing incidence of pneumococcal disease has also been reported by other UK studies 14 17 22 23, with Pick et al reporting incidence of pneumococcal pneumonia of 32.2 and 48.2 per 100,000 population in 2013 and 2018 respectively ¹⁴. Using previously published estimates that up to 20% of adults hospitalised with pneumococcal pneumonia develop a pleural effusion 12, estimates of parapneumonic effusion incidence from that study would be 6.4 and 9.6 in 2013 and 2018, which are similar to the incidence rates of 5.0 and 9.8 observed in the same years in this study. Recent national epidemiological studies of pleural infection from North America also show significant increases in pleural infection rates both in children²⁴ and adults²⁵. Likewise, a Danish study from 1997-2001, showed steadily rising pleural infection rates in the elderly²⁶ and a UK study showed annual rises in adult pleural infections from 2008-17²⁷, most marked in over 60-year-old individuals with a 194% increase over the decade. The introduction of PCV7 into the UK childhood vaccination programme in 2006 was followed by a decrease in adult pleural effusions attributable to PCV7 vaccine serotypes in this study. Notably, all parapneumonic effusions due to PCV7 serotypes after 2011 were SPE

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

and due to serotypes 14 and 19F, with no cases of pleural infection. After 2010, all PCV13 pleural infection cases were attributable to serotypes 1 or 3, highlighting the predilection of these serotypes for causing pleural disease. The inclusion of patients with a positive pneumococcal urinary-antigen test permitted serotype identification although in only 38% of cases, despite linkage with the UK Health Security Agency (UKHSA) national reference laboratory. Nevertheless, the trends in serotype and vaccine-serotype group that we found in this cohort are similar to those reported by other surveillance studies. Additionally, the trends in serotype distribution partially align with national serotype trends, showing reductions in both PCV7 serotype and serotype 1 adult IPD incidence¹¹, and both serotypes are prevalent in studies of pleural infection in children²⁸. In the UK, large reductions in vaccine-serotype adult IPD were offset by increases in non-PCV13 IPD^{11 17 22}, a trend also apparent in this patient cohort, with non-PCV13 disease increasing from 30% to 60% of known serotype disease. Pick et al showed an increase in non-PCV13 serotype pneumococcal pneumonia from 2014/15 onwards 14 as well as an overall increase in PCV13-7 serotype disease, in contrast to trends reported in this study. However, Pick et al report all respiratory infection and therefore as these are the first data on serotype trends in adult pneumococcal pleural disease since paediatric PCV introduction in the UK, differences reported here may be attributable to differences within patients with pleural infection. This comparison with other UK surveillance studies provides some reassurance that the results here are representative of parapneumonic effusions related to *Streptococcus pneumoniae*. This highlights the difficulty in undertaking accurate disease surveillance, which cannot be conducted without thorough microbiological testing of patients. However, such surveillance is critical for monitoring both the direct and indirect effects of current pneumococcal vaccinations and predicting the effect of novel vaccines before implementation.

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

Serotype affects pneumococcal resistance to innate immunity, duration of nasopharyngeal colonisation, the number of episodes of invasive disease per colonisation event, mortality and disease severity²⁹⁻³¹. The two PCV13-7 serotypes which continued to cause pneumococcal pleural infection following PCV13 introduction are notable serotypes as they have unusual polysaccharide capsules. Serotype 1 expresses a zwitterionic and structurally diverse polysaccharide capsule, which uniquely may act as a T-cell dependent antigen³², is rarely isolated in asymptomatic nasopharyngeal colonization but is commonly isolated in IPD²⁹. frequently causing invasive pneumonia³³. Serotype 1 is more likely to be identified in young patients, and some studies find it is the most frequent cause of pneumococcal pleural infection and responsible for increasing disease incidence²⁹. Interestingly, in this cohort, patients with serotype 1 pleural infection had a better survival rate despite higher RAPID score than those with serotype 3. This may reflect the younger age and lower cardiac disease rate in patients with serotype 1 pleural infection, as well as increased likelihood of surgical intervention in these cases. In contrast, the serotype 3 polysaccharide capsule is large, resulting in a highly mucoid appearance, and is one of a few capsules produced by synthasemediated synthesis³⁴. Serotype 3 also causes considerable disease burden^{2 28}, is the most common overall cause of pneumonia in the USA³⁵, is highly invasive²⁹ and associated with increased mortality³⁰. Distinct lineages exist within serotype 3 clonal complex 180, and recent clade distributions shift has led to the emergence and expansion of clade II³⁶ 37, which now represents 50% serotype 3 IPD in the UK³⁸. We could not determine serotype 3 clade grouping in this analysis, but clade II emergence may, at least in part, explain serotype 3 disease persistence.

Interestingly, our data suggest that pneumococcal pleural infection is associated with improved survival up to one-year compared to patients with pneumococcal SPE. We found a

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

high burden of pre-existing medical comorbidity in patients with both SPE and pleural infection, in keeping with a large systematic review which found that 72% of patients with pleural infection had at least one significant comorbidity with high levels of pre-existing cardiac and respiratory diseases³⁹. However, patients with SPE had a trend towards a high burden of underlying cardiovascular disease, chronic obstructive pulmonary disease, solidorgan and haematological malignancy (Supplementary Data 3), which may account for differences in survival. It should be noted that <30% of effusions are known to have more than one aetiology⁴⁰, with many having a cardiac or renal component. Thus, it can be difficult to determine the full aetiology of a pleural effusion, and pneumococcal SPEs may often be due to dual aetiology e.g. infection, causing atrial fibrillation and cardiac failure. In this cohort, pre-existing cardiac disease and bilateral effusions were more common in patients with SPE. Previous data suggest individuals with pneumonia and cardiac failure have higher mortality rates⁴¹, and bilateral effusions are associated with worse outcomes^{41 42}. Hence, whilst some effusions reflect more severe lung inflammation, others may reflect concomitant comorbidity in the host; either factor can account for worse outcome and may explain this finding in our cohort. Further, the high proportion of patients undergoing surgical intervention, which is associated with improved outcomes 43 44, may have improved patient survival in the pleural infection patients. Of note, in our pleural infection group, no deaths occurred within 1-year of presentation in those who underwent surgery compared to 24% mortality in patients who did not. Although patients who did not undergo surgery were older than those who did, these data highlight the importance of appropriate surgical intervention in patients with pleural infection.

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

As shown in the initial validation and subsequent cohort studies of the RAPID score^{20 21}, a high score was strongly associated with the risk of mortality by 3-months. Study patients in the low-risk group had a 3% (95% C.I 0.7 to 15%) risk of 90-day mortality compared to 57% (95% C.I. 28% to 82% P<0.01), for those with a high risk score, while there was much less difference in survival between those in low and medium RAPID groups, as reported by others^{21 45}. There was a positive association between pleural fluid purulence and survival: this relationship has been demonstrated in cohorts that were not restricted by causative organism, suggesting it is disease and not pathogen specific²⁰. This study identified patients with pneumococcal infection and parapneumonic effusions within a defined geographical area, covering a population of approximately one million adults, and encompassed 3 large hospitals with 100,000 unplanned adult admissions annually. One of these hospitals is the regional thoracic surgery centre, whilst another has a specialist pleural disease service, possibly increasing the accuracy of the clinical data presented here. We captured disease and serotype trends over 13 years, spanning PCV introduction. By linking with the UKHSA national reference laboratory we were able to report serotype where it was available. Importantly, the epidemiological data were supported with detailed clinical information for individual patients, including short- and long-term outcomes. However, this study also has limitations in addition to those discussed above. This is a retrospective observational study; therefore, only information documented in clinical records could be included and patients were managed at the discretion of individual physicians. The pneumococcal serotype data was only obtainable through standard-of-care testing and by sterile site culture, as BinaxNOW does not derive serotype. Despite linkage with the national reference service, we were only able to determine the serotype in 38% of pneumococcal cases in this cohort. As a regional study, the findings here may not be representative of other

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

populations; although, our serotype trends are comparable to other UK national and regional reports. We note an expanding total and older adult population in Bath and Bristol during the study, which may affect disease incidence. Additionally, changes in patient or physician treatment preferences, including threshold for referral to secondary care, diagnostic testing and treatment which may have occurred and impacted disease incidence estimates 46. We included patients who tested positive for pneumococcus using the BinaxNOW® urinary antigen test, which has a known sensitivity of 65% and prolonged positive test result after exposure to pneumococcus⁴⁷. Lastly, different methodologies were used to identify pneumococcal serotypes during the study period; whole genomic sequencing was only routinely used by UKHSA from October 2017, and therefore earlier isolates did not have this performed. Overall, we found an increasing incidence of pneumococcal parapneumonic effusion in this UK population. The proportion of disease attributable to PCV7 serotypes fell after this vaccine was introduced into the UK childhood vaccination programme; however, disease attributable serotypes 1 and 3 did not show decline following PCV13 vaccine rollout. Further increase in non-vaccine serotype disease contributed to increasing disease incidence. Patients with SPE had reduced one-year survival compared to those with pleural infection, which may be attributable to the burden of underlying pre-existing diseases. We also found reassuring evidence that surgical management was associated with improved patient outcomes in patients with pneumococcal pleural infection. Future research should aim to determine if S. pneumoniae serotype is predictive of mortality risk in adults with pneumococcal parapneumonic effusions.

The authors would like to acknowledge the research teams at The Royal United, North Bristol and University Hospitals of Bristol and Weston NHS Trusts.

DATA SHARING

The data used in this study are sensitive and cannot be made publicly available without breaching patient confidentiality rules. Therefore, individual participant data and a data dictionary is not available to other researchers.

REFERENCES

486

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507 508

509

510

511

512

513

514

519

520

521

522

- 487 1. Vallés X, Marcos A, Pinart M, et al. Hospitalized Community-Acquired Pneumonia Due to 488 Streptococcus pneumoniae: Has Resistance to Antibiotics 489 2006;130(3):800-06. doi: https://doi.org/10.1378/chest.130.3.800
- 490 2. Cillóniz C, Ewig S, Polverino E, et al. Pulmonary complications of pneumococcal community-491 acquired pneumonia: incidence, predictors, and outcomes. Clinical Microbiology and 492 Infection 2012;18(11):1134-42. doi: https://doi.org/10.1111/j.1469-0691.2011.03692.x
 - 3. Chalmers JD, Singanayagam A, Murray MP, et al. Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia. *Thorax* 2009;64(7):592. doi: 10.1136/thx.2008.105080
 - 4. Falguera M, Carratalà J, Bielsa S, et al. Predictive factors, microbiology and outcome of patients with parapheumonic effusion. European Respiratory Journal 2011;38(5):1173. doi: 10.1183/09031936.00000211
 - 5. Whitney CG, Farley MM, Hadler J, et al. Decline in Invasive Pneumococcal Disease after the Introduction of Protein-Polysaccharide Conjugate Vaccine. New England Journal of Medicine 2003;348(18):1737-46. doi: 10.1056/NEJMoa022823
 - 6. Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-Valent Pneumococcal Conjugate Vaccination in Invasive Pneumococcal Disease Incidence and Mortality. Clinical Infectious Diseases 2014;59(8):1066-73. doi: 10.1093/cid/ciu524
 - 7. Kelly MM, Coller RJ, Kohler JE, et al. Trends in Hospital Treatment of Empyema in Children in the United States. The Journal of **Pediatrics** 2018;202:245-51.e1. https://doi.org/10.1016/j.jpeds.2018.07.004
 - 8. Weinberger DM, Harboe ZB, Shapiro ED. Developing Better Pneumococcal Vaccines for Adults. JAMA Internal Medicine 2017;177(3):303-04. doi: 10.1001/jamainternmed.2016.8289
 - 9. Wagenvoort GHJ, Sanders EAM, Vlaminckx BJ, et al. Invasive pneumococcal disease: Clinical outcomes and patient characteristics 2-6 years after introduction of 7-valent pneumococcal conjugate vaccine compared to the pre-vaccine period, the Netherlands. Vaccine 2016;34(8):1077-85. doi: https://doi.org/10.1016/j.vaccine.2015.12.066
 - 10. UKHSA. Pneumococcal: the Green book2020:1-13.
- 515 11. Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive 516 pneumococcal disease in England and Wales, 2000-2013;17: a prospective national 517 observational cohort study. The Lancet Infectious Diseases 2018;18(4):441-51. doi: 518 10.1016/S1473-3099(18)30052-5
 - 12. Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011;11(10):760-68. doi: 10.1016/S1473-3099(11)70090-1 [published Online First: 2011/05/27]
- 523 13. Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate 524 vaccine on invasive pneumococcal disease in England and Wales 4 years after its 525 introduction: an observational cohort study. Lancet Infect Dis 2015;15(5):535-43. doi: 526 10.1016/S1473-3099(15)70044-7 [published Online First: 2015/03/20]
- 527 14. Pick H, Daniel P, Rodrigo C, et al. Pneumococcal serotype trends, surveillance and risk factors in 528 UK adult pneumonia, 2013-18. Thorax 2020;75(1):38. doi: 10.1136/thoraxjnl-2019-213725
- 529 15. Shebl E PM. Parapneumonic Pleural Effusions And Empyema Thoracis. StatPearls [Internet]: 530 StatPearls Publishing 2022.
- 531 16. Hyams C, Amin-Chowdhury Z, Fry NK, et al. Streptococcus Pneumoniae septic arthritis in adults in 532 Bristol and Bath, United Kingdom, 2006-2018: a 13-year retrospective observational cohort 533 Emerging Microbes & Infections 2021;10(1):1369-77.

534 10.1080/22221751.2021.1945955

- 535 17. Amin-Chowdhury Z, Collins S, Sheppard C, et al. Characteristics of Invasive Pneumococcal Disease
 536 Caused by Emerging Serotypes After the Introduction of the 13-Valent Pneumococcal
 537 Conjugate Vaccine in England: A Prospective Observational Cohort Study, 2014–2018.
 538 Clinical Infectious Diseases 2020 doi: 10.1093/cid/ciaa043
- 539 18. Light RW, Girard WM, Jenkinson SG, et al. Parapneumonic effusions. *Am J Med* 1980;69(4):507-540 12. doi: 10.1016/0002-9343(80)90460-x [published Online First: 1980/10/01]
- 541 19. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. *Thorax* 2003;58(5):377. doi: 10.1136/thorax.58.5.377
- 20. Rahman NM, Kahan BC, Miller RF, et al. A Clinical Score (RAPID) to Identify Those at Risk for Poor Outcome at Presentation in Patients With Pleural Infection. *Chest* 2014;145(4):848-55. doi: https://doi.org/10.1378/chest.13-1558

548

549

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

- 21. Corcoran JP, Psallidas I, Gerry S, et al. Prospective validation of the RAPID clinical risk prediction score in adult patients with pleural infection: the PILOT study. *European Respiratory Journal* 2020:2000130. doi: 10.1183/13993003.00130-2020
- 22. Houseman C, Hughes GJ, Chapman KE, et al. Increased Invasive Pneumococcal Disease, North East England, UK. *Emerging infectious diseases* 2017;23(1):122-26. doi: 10.3201/eid2301.160897
- 23. Abram SGF, Alvand A, Judge A, et al. Mortality and adverse joint outcomes following septic arthritis of the native knee: a longitudinal cohort study of patients receiving arthroscopic washout. The Lancet Infectious Diseases 2020;20(3):341-49. doi: https://doi.org/10.1016/S1473-3099(19)30419-0
- 557 24. Finley C, Clifton J, Fitzgerald JM, et al. Empyema: an increasing concern in Canada. *Canadian* respiratory journal 2008;15(2):85-89. doi: 10.1155/2008/975312
- 559 25. Mummadi SR, Stoller JK, Lopez R, et al. Epidemiology of Adult Pleural Disease in the United States. *Chest* 2021;160(4):1534-51. doi: https://doi.org/10.1016/j.chest.2021.05.026
 - 26. Søgaard M, Nielsen RB, Nørgaard M, et al. Incidence, Length of Stay, and Prognosis of Hospitalized Patients With Pleural Empyema: A 15-Year Danish Nationwide Cohort Study. Chest 2014;145(1):189-92. doi: https://doi.org/10.1378/chest.13-1912
 - 27. Arnold DT, Hamilton FW, Morris TT, et al. Epidemiology of pleural empyema in English hospitals and the impact of influenza. *European Respiratory Journal* 2020:2003546. doi: 10.1183/13993003.03546-2020
 - 28. Fletcher MA, Schmitt HJ, Syrochkina M, et al. Pneumococcal empyema and complicated pneumonias: global trends in incidence, prevalence, and serotype epidemiology. *European Journal of Clinical Microbiology & Infectious Diseases* 2014;33(6):879-910. doi: 10.1007/s10096-014-2062-6
 - 29. Brueggemann AB, Griffiths DT, Meats E, et al. Clonal Relationships between Invasive and Carriage Streptococcus pneumoniae and Serotype- and Clone-Specific Differences in Invasive Disease Potential. *The Journal of Infectious Diseases* 2003;187(9):1424-32. doi: 10.1086/374624
 - 30. Weinberger DM, Harboe ZB, Sanders EAM, et al. Association of Serotype with Risk of Death Due to Pneumococcal Pneumonia: A Meta-Analysis. *Clinical Infectious Diseases* 2010;51(6):692-99. doi: 10.1086/655828
- 31. Hyams C, Yuste J, Bax K, et al. Streptococcus pneumoniae resistance to complement-mediated immunity is dependent on the capsular serotype. *Infect Immun* 2010;78(2):716-25. doi: 10.1128/IAI.01056-09 [published Online First: 2009/11/30]
- 32. Kaushal N, Kumari S, Jhelum H, et al. In vitro and in vivo characterization of the interaction, proinflammatory, immunomodulatory and antigenic properties of capsular polysaccharide from Streptococcus pneumoniae serotype 1. International Journal of Biological Macromolecules 2020;143:521-32. doi: https://doi.org/10.1016/j.ijbiomac.2019.12.022

- 33. Bergman K, Härnqvist T, Backhaus E, et al. Invasive pneumococcal disease in persons with predisposing factors is dominated by non-vaccine serotypes in Southwest Sweden. *BMC Infectious Diseases* 2021;21(1):756. doi: 10.1186/s12879-021-06430-y
- 34. Luck JN, Tettelin H, Orihuela CJ. Sugar-Coated Killer: Serotype 3 Pneumococcal Disease. *Frontiers* in Cellular and Infection Microbiology 2020;10
- 589 35. Pande A, Nasir S, Rueda AM, et al. The Incidence of Necrotizing Changes in Adults With Pneumococcal Pneumonia. *Clinical Infectious Diseases* 2012;54(1):10-16. doi: 10.1093/cid/cir749
- 36. Azarian T, Mitchell PK, Georgieva M, et al. Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci. *PLOS Pathogens* 2018;14(11):e1007438. doi: 10.1371/journal.ppat.1007438
- 595 37. Croucher NJ, Mitchell AM, Gould KA, et al. Dominant Role of Nucleotide Substitution in the 596 Diversification of Serotype 3 Pneumococci over Decades and during a Single Infection. *PLOS* 597 *Genetics* 2013;9(10):e1003868. doi: 10.1371/journal.pgen.1003868

599

600

607

608

609

625

- 38. Groves N, Sheppard CL, Litt D, et al. Evolution of Streptococcus pneumoniae Serotype 3 in England and Wales: A Major Vaccine Evader. *Genes* 2019;10(11) doi: 10.3390/genes10110845
- 601 39. Cargill TN, Hassan M, Corcoran JP, et al. A systematic review of comorbidities and outcomes of adult patients with pleural infection. *European Respiratory Journal* 2019:1900541. doi: 10.1183/13993003.00541-2019
- 604 40. Bintcliffe OJ, Hooper CE, Rider IJ, et al. Unilateral Pleural Effusions with More Than One Apparent 605 Etiology. A Prospective Observational Study. *Annals of the American Thoracic Society* 2016;13(7):1050-56. doi: 10.1513/AnnalsATS.201601-082OC
 - 41. Hasley PB, Albaum MN, Li YH, et al. Do pulmonary radiographic findings at presentation predict mortality in patients with community-acquired pneumonia? *Arch Intern Med* 1996;156(19):2206-12. [published Online First: 1996/10/28]
- 610 42. Dean NC, Jones BE, Jones JP, et al. Impact of an Electronic Clinical Decision Support Tool for Emergency Department Patients With Pneumonia. *Ann Emerg Med* 2015;66(5):511-20. doi: 10.1016/j.annemergmed.2015.02.003 [published Online First: 2015/03/03]
- 43. Federici S, Bédat B, Hayau J, et al. Outcome of parapneumonic empyema managed surgically or by fibrinolysis: a multicenter study. *Journal of Thoracic Disease* 2021;13(11):6381-89.
- 615 44. Wait MA, Sharma S, Hohn J, et al. A randomized trial of empyema therapy. *Chest* 1997;111(6):1548-51. doi: 10.1378/chest.111.6.1548 [published Online First: 1997/06/01]
- 45. White HD, Henry C, Stock EM, et al. Predicting Long-Term Outcomes in Pleural Infections. RAPID
 Score for Risk Stratification. *Annals of the American Thoracic Society* 2015;12(9):1310-16.
 doi: 10.1513/AnnalsATS.201505-2720C
- 46. Maguire D, Dunn P, McKenna H. How hospital activity in the NHS in England has changed over time. 2016
- 47. Hyams C, Williams OM, Williams P. Urinary antigen testing for pneumococcal pneumonia: is there evidence to make its use uncommon in clinical practice? *ERJ Open Research* 2020;6(1):00223-2019. doi: 10.1183/23120541.00223-2019

628

629

630

631

632

633

634

635

636

637

638

639

640


641


642


643


644

FIGURE LEGENDS Figure 1: Vaccine group serotype trends in pneumococcal parapneumonic effusions in Bristol, UK 2006-2018 (A) Incidence of pneumococcal parapneumonic effusion (per 100,000 adults), calculated using adult population data from the Office of National Statistics (Supplementary Data 5). (B) proportion of serotyped disease caused by vaccine serotype group as shown from 2006-18. Dashed lines show the introduction of paediatric PCV7 and PCV13. (C) proportion of serotyped disease caused by the major individual serotypes from 2006-18. The black line shows the trend in proportion of disease, with the grey area representing the 95% confidence interval. Figure 2: 1-year survival in patients with pneumococcal parapneumonic effusions (A) Kaplan-Meier survival curve and number at risk for patients with simple parapneumonic effusion (SPE) (red line) and pleural infection (blue line). (B) Kaplan-Meier survival curve and number at risk for patients with pneumococcal pleural infection for low (red line), medium (blue line) ad high (black line) RAPID score groups. The number of subjects at risk immediately before each time point is listed in a numbers-at-risk table.











Days	0	56	112	154	204	250	300	365
SPE	459	385	370	358	346	334	316	309
Pleural infection	100	89	86	85	84	83	82	80

